© Springer International Publishing Switzerland 2016Janusz K. Rybakowski and Alessandro Serretti (eds.)Genetic Influences on Response to Drug Treatment for Major Psychiatric Disorders10.1007/978-3-319-27040-1_7 7. Practical Application of Pharmacogenetics of Antipsychotic, Antidepressant, and Mood-Stabilizing Drugs Alessandro Serretti1 and…
Mood stabilizer Neurobiology area Positive findings Authors Lithium Neurotransmission 5–HTT gene TPH gene DRD1 gene FYN gene Serretti et al. [72, 74], Rybakowski et al. [59], Tharoor et al. [87]…
Medication adherence Adverse effects/intolerance Adequate treatment duration Outcome definition (improvement/response/remission) Inclusion of non-antidepressant concomitant treatments Phenocopies/medical comorbidity Comparison groups for TRD cohort A related problem is the range of medical…
Gene Function Polymorphism(s) Main finding(s) Clinical applications References SLC6A4 Serotonin transporter 5-HTTLPR S allele worse response in Caucasians treated with SSRIs and higher risk of SSRI-induced side effects Included in…
Pharmacodynamic profile Pharmacokinetic profile Haloperidol D2, D3, D4 CYP2D6, CYP3A4 Chlorpromazine D2, D3, D4, 5-HT2A, 5-HT2C, 5-HT6 CYP2D6, CYP1A2 Clozapine 5-HT2A, 5-HT2C, 5-HT6, D4, D2, H1, M1, ADR1A CYP1A2,…
Gene Polymorphism Main findings CYP1A2 (*1F, −163C>А, rs762551) CC genotype and/or C allele are possible risk factors for tardive dyskinesia SLC18A2 rs2015586 C allele can be a risk variant for…
Author Subjects Treatment Brain areas Results Vakili et al. [100] 38 patients (17 males, mean age 38.5 ± 10.0 years) 20 healthy controls (9 males, mean age 40.3 ± 10.4 years) Fluoxetine, 20 mg/day…
